All eyes were on a California-based %Biotech company on Monday after a few announcements came across the newswires earlier in the session.
Shares of %LuciraHealth () were soaring to start the week after to company announced it was seeking a strategic partner to help resume manufacturing of its recently approved Covid-19 & Flue test. Shares climbed up to $0.7502/share (+435.86%) at the session high.
Lucira Health Inc is a %MedicalTechnology company focused on the development and commercialization of transformative and innovative infectious disease test kits. It has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and user-friendly test kit that is powered by two AA batteries and fit in the palm of a hand. The company's initial focus is within respiratory diseases, and initially for COVID-19 and influenza Types A and B indications.